Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2019

Open Access 01-10-2019 | Rectal Cancer | Special Article

Recommendations for follow-up of colorectal cancer survivors

Authors: R. Vera, J. Aparicio, F. Carballo, M. Esteva, E. González-Flores, J. Santianes, F. Santolaya, J. M. Fernández-Cebrián

Published in: Clinical and Translational Oncology | Issue 10/2019

Login to get access

Abstract

Colorectal cancer (CRC) is one of the tumours with the highest incidence and mortality in the Spanish population. Nevertheless, the advances in prevention and treatment have contributed to an increased number of patients who survive for prolonged periods of time. In addition, despite recurrences, improved survival following metastasis resection is likewise on the rise. This underscores the importance of carrying out follow-up programmes even in low-risk patients for the early detection of recurrence. The main objective of this article is to provide a set of recommendations for optimising the follow-up of CRC survivors as well as for managing the sequelae that result from either pharmacological or surgical treatment.
Literature
1.
2.
Bohm B, Schwenk W, Hucke HP, Stock W. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993;36:280–6.CrossRefPubMed
3.
Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.CrossRefPubMedPubMedCentral
4.
Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Int J Colorectal Dis. 1997;12:329–34.CrossRefPubMed
5.
El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65:428–55.CrossRefPubMedPubMedCentral
6.
Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465–70.CrossRefPubMed
7.
8.
Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology. 2016;150(758–68):e11.
9.
Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi64–72.CrossRefPubMed
10.
Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21:v70–7.CrossRefPubMed
11.
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:22–40.CrossRef
12.
13.
14.
Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;11:CD002200.PubMed
15.
Nayor J, Saltzman JR, Campbell EJ, Perencevich ML, Jajoo K, Richter JM. Impact of physician compliance with colonoscopy surveillance guidelines on interval colorectal cancer. Gastrointest Endosc. 2017;85:1263–70.CrossRefPubMed
16.
Erenay FS, Alagoz O, Banerjee R, Said A, Cima RR. Cost-effectiveness of alternative colonoscopy surveillance strategies to mitigate metachronous colorectal cancer incidence. Cancer. 2016;122:2560–70.CrossRefPubMedPubMedCentral
17.
Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015;58:713–25.CrossRefPubMed
18.
Maurel J, Gravalos C, Rivera F, Vera R, González-Flores E, SEOM. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clin Transl Oncol. 2013;15:991–1995.CrossRefPubMed
19.
González-Flores E, Losa F, Pericay C, Polo E, Roselló S, Safont MJ, et al. SEOM Clinical Guideline of localized rectal cancer (2016). Clin Transl Oncol. 2016;18:1163–71.CrossRefPubMedPubMedCentral
20.
Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274–80.CrossRefPubMed
21.
Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015;26:644–56.CrossRefPubMed
22.
Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM, et al. A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg. 2013;148:769–77.CrossRefPubMedPubMedCentral
23.
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263–70.CrossRefPubMed
24.
Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015;47:529–31.CrossRefPubMed
25.
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569–74.CrossRefPubMed
26.
Rodríguez-Moranta F, Salo J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386–93.CrossRefPubMed
27.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.CrossRefPubMed
28.
29.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;2014:CD005228.
30.
Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:1228–34.CrossRefPubMed
31.
Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100:1377–87.CrossRefPubMed
32.
Lange MM, Martz JE, Ramdeen B, Brooks V, Boachie-Adjei K, van de Velde CJ, et al. Long-term results of rectal cancer surgery with a systematical operative approach. Ann Surg Oncol. 2013;20:1806–15.CrossRefPubMed
33.
Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.CrossRefPubMed
34.
Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg. 1994;220:676–82.CrossRefPubMedPubMedCentral
35.
36.
de la Portilla F, Rada R, Vega J, González CA, Cisneros N, Maldonado VH. Evaluation of the use of posterior tibial nerve stimulation for the treatment of fecal incontinence: preliminary results of a prospective study. Dis Colon Rectum. 2009;52:1427–33.CrossRefPubMed
37.
Moya P, Arroyo A, Soriano-Irigaray L, Frangi A, Candela Polo F, Calpena Rico R. Sacral nerve stimulation in patients with severe fecal incontinence after rectal resection. Tech Coloproctol. 2012;16:263–4.CrossRefPubMed
38.
Ramage L, Qiu S, Kontovounisios C, Tekkis P, Rasheed S, Tan E. A systematic review of sacral nerve stimulation for low anterior resection syndrome. Colorectal Dis. 2015;17:762–71.CrossRefPubMed
39.
Turina M, Mulhall AM, Mahid SS, Yashar C, Galandiuk S. Frequency and surgical management of chronic complications related to pelvic radiation. Arch Surg. 2008;143:46–52 (discussion).CrossRefPubMed
40.
Babb RR. Radiation proctitis: a review. Am J Gastroenterol. 1996;91:1309–11.PubMed
41.
Small W Jr, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research? JAMA. 2005;294:2635–7.CrossRefPubMed
42.
Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol. 2007;30:333–9.CrossRefPubMed
43.
Lange MM, Maas CP, Marijnen CA, Wiggers T, Rutten HJ, Kranenbarg EK, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008;95:1020–8.CrossRefPubMed
44.
Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control. 2010;17:44–51.CrossRefPubMed
45.
Brown JC, Damjanov N, Courneya KS, Troxel AB, Zemel BS, Rickels MR, et al. A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors. Psychooncology. 2018;27:1221–8.CrossRefPubMedPubMedCentral
46.
Lee MK, Kim JY, Kim DI, Kang DW, Park JH, Ahn KY, et al. Effect of home-based exercise intervention on fasting insulin and adipocytokines in colorectal cancer survivors: a randomized controlled trial. Metabolism. 2017;76:23–31.CrossRefPubMed
47.
Moug SJ, Bryce A, Mutrie N, Anderson AS. Lifestyle interventions are feasible in patients with colorectal cancer with potential short-term health benefits: a systematic review. Int J Colorectal Dis. 2017;32:765–75.CrossRefPubMedPubMedCentral
48.
49.
50.
Wu W, Guo F, Ye J, Li Y, Shi D, Fang D, et al. Pre- and post-diagnosis physical activity is associated with survival benefits of colorectal cancer patients: a systematic review and meta-analysis. Oncotarget. 2016;7:52095–103.PubMedPubMedCentral
51.
52.
Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–9.CrossRefPubMed
53.
Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9.CrossRefPubMed
54.
Serra-Rexach JA, Jiménez AB, García-Alhambra MA, Pla R, Vidán M, Rodríguez P, et al. Differences in the therapeutic approach to colorectal cancer in young and elderly patients. Oncologist. 2012;17:1277–85.CrossRefPubMedPubMedCentral
55.
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595–603.CrossRefPubMedPubMedCentral
56.
Zullig LL, Goldstein KM, Bosworth HB, Andrews SM, Danus S, Jackson GL, et al. Chronic disease management perspectives of colorectal cancer survivors using the Veterans Affairs healthcare system: a qualitative analysis. BMC Health Serv Res. 2018;18:171.CrossRefPubMedPubMedCentral
57.
Urquhart R, Lethbridge L, Porter GA. Patterns of cancer centre follow-up care for survivors of breast, colorectal, gynecologic, and prostate cancer. Curr Oncol. 2017;24:360–6.CrossRefPubMedPubMedCentral
58.
Correa-Casado M, Granero-Molina J, Hernández-Padilla JM. Fernández-Sola C [Transferring palliative-care patients from hospital to community care: A qualitative study]. Aten Primaria. 2017;49:326–34.CrossRefPubMed
59.
Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994;219:174–82.PubMed
60.
Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:519–28 (Localized colon cancer, version 3.2013).CrossRefPubMed
61.
62.
Urquhart R, Folkes A, Babineau J, Grunfeld E. Views of breast and colorectal cancer survivors on their routine follow-up care. Curr Oncol. 2012;19:294–301.CrossRefPubMedPubMedCentral
63.
Urquhart R, Folkes A, Porter G, Kendell C, Cox M, Dewar R, et al. Population-based longitudinal study of follow-up care for patients with colorectal cancer in Nova Scotia. J Oncol Pract. 2012;8:246–52.CrossRefPubMedPubMedCentral
64.
Duineveld LA, van Asselt KM, Bemelman WA, Smits AB, Tanis PJ, van Weert HC, et al. Symptomatic and asymptomatic colon cancer recurrence: a multicenter cohort study. Ann Fam Med. 2016;14:215–20.CrossRefPubMedPubMedCentral
Metadata
Title
Recommendations for follow-up of colorectal cancer survivors
Authors
R. Vera
J. Aparicio
F. Carballo
M. Esteva
E. González-Flores
J. Santianes
F. Santolaya
J. M. Fernández-Cebrián
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 10/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02059-1

Other articles of this Issue 10/2019

Clinical and Translational Oncology 10/2019 Go to the issue

Brief Research Article

ΔNp73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells)

Research Article

The detection and clinical significance of peripheral regulatory CD4+CD25hiCD127low T cells in patients with non-small cell lung cancer

Research Article

Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis

Research Article

Expression of PDK1 in malignant pheochromocytoma as a new promising potential therapeutic target

Research Article

Results of a nationwide survey on multidisciplinary teams on thyroid cancer in Spain

Correction

Correction to: Recommendations for follow‑up of colorectal cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits